Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidkılıç, nülüfer/HJP-0626-2023
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.contributor.authorTurkmen, Esma
dc.contributor.authorErdogan, Bulent
dc.contributor.authorKodaz, Hilmi
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorOnal, Yilmaz
dc.contributor.authorUzunoglu, Sernaz
dc.contributor.authorKilic, Nilufer
dc.date.accessioned2024-06-12T11:08:25Z
dc.date.available2024-06-12T11:08:25Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose : The aim of this study was to define the factors that affect response and post-progression survival of metastatic gastric cancer (MGC) and gastroesophageal junction cancer (GEJ) patients treated with second-line chemotherapy. Methods : We retrospectively reviewed the data of 59 patients with MGC or GEJ adenocarcinoma who received second-line treatment. Results : The median age was 54 years old (26-77). Response to second-line treatment was strongly associated with disease control with first-line treatment (p < 0.01). Median progression-free survival (PFS), overall survival (OS) and post-progression survival (PPS) were 3.2 (95% CI : 2.63-3.80), 6.5 (95% CI : 3.78-9.35) and 2.7 months (95% CI : 1.89-3.68), respectively. PFS (r = 0.55, p < 0.01) and PPS (r = 0.89, p < 0.01) were correlated with OS. Response to second-line treatment was independently related to PFS (HR : 0.12 95% CI : 0.53-0.26, p < 0.001). Having an ECOG 0 performance status (HR : 0.42; 95% CI : 0.21-0.86, p = 0.02) and response to second-line therapy (HR : 0.47; 95% CI : 0.25-0.85, p = 0.01) were independently associated with OS. Conclusion : PPS and PFS were correlated with OS after second-line treatment of MGC. Response to second-line treatment prolonged OS by increasing PFS, and having an ECOG 0 PS prolonged OS by increasing PPS.en_US
dc.identifier.endpage215en_US
dc.identifier.issn1784-3227
dc.identifier.issue2en_US
dc.identifier.pmid27382940en_US
dc.identifier.scopus2-s2.0-84982786664en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage211en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22427
dc.identifier.volume79en_US
dc.identifier.wosWOS:000384746300007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherUniv Catholique Louvain-Uclen_US
dc.relation.ispartofActa Gastro-Enterologica Belgicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMetastatic Gastric Canceren_US
dc.subjectPost Progression Survivalen_US
dc.subjectOverall Survival Performance Statusen_US
dc.subjectSecond-Line Treatmenten_US
dc.subjectPost Progression Survivalen_US
dc.subjectRandomized Phase-Iiien_US
dc.subjectSupportive Careen_US
dc.subjectChemotherapyen_US
dc.subjectCombinationen_US
dc.subjectStatisticsen_US
dc.subjectIrinotecanen_US
dc.subjectPlusen_US
dc.titlePost progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatmenten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu